Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01896622 · ClinicalTrials.gov registry record · Phase 1
The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers
A Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01896622 is a Phase 1 study that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 40 participants.
The verdict
NCT01896622, a Phase 1 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Background: \- People who have the human immunodeficiency virus (HIV) often take several medications to control their disease. They may also need to take medicine to prevent blood clots. Taking both kinds of medicine together can cause bleeding or other problems. But this might not happen if the medications are taken at different times. Researchers will study two particular HIV drugs (ritonavir and cobicistat) and how they interact with blood clot medications. Objectives: -To understand how HIV medicine and blood clot medicine interact, so doctors can choose what to prescribe for people who take both. Eligibility: \- Healthy adults between 18 and 70 years old who are not on any medications. Design: * Participants will be screened with a physical exam and medical history. Blood samples will be collected. Urine samples will be collected from participants who might become pregnant. * Participants will visit the National Institutes of Health 7 times after the screening visit. Three visits will last about 12 hours. The other 4 will last about 1 hour. * Participants will take a daily dose of either study medication for 22 days. They will keep a diary of medicine they take and any side effects. * Treatment will be monitored with blood tests over about 2 months. * When the study of one drug is completed, the next drug study will begin with a different group of participants.
Interventions
- DRUG Ritonavir
- DRUG Cobicistat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-06-18 |
| Est. Completion | 2017-01-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01896622
The ClinicalTrials.gov registry entry for NCT01896622 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ritonavir is the first listed.
NCT01896622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01896622 about?
NCT01896622 is a clinical study titled "The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers". Background: \- People who have the human immunodeficiency virus (HIV) often take several medications to control their disease. They may also need to take medicine to prevent blood clots. Taking both kinds of medicine together can cause bleeding or other problems. But this might not happen if the me...
What is the current status of trial NCT01896622?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2013-06-18. Estimated completion is 2017-01-17.
What interventions are being tested in trial NCT01896622?
The interventions under investigation include: Ritonavir (DRUG), Cobicistat (DRUG).
Who is sponsoring clinical trial NCT01896622?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.